"10.1371_journal.pone.0132233","plos one","2015-07-06T00:00:00Z","Eiji Kirino; Hideyuki Imagawa; Taro Goto; William Montgomery","Department of Psychiatry, Juntendo University Shizuoka Hospital, Izunokunishi City, Shizuoka, Japan; Eli Lilly Japan K.K., Chuo-ku, Kobe City, Hyogo, Japan; Eli Lilly Australia Pty Ltd, Sydney, Australia","Conceived and designed the experiments: EK HI TG WM. Analyzed the data: EK HI TG WM. Wrote the paper: EK HI TG WM.","Eli Lilly Japan K.K. provided funds to Kantar Health for the conduct of the web-based survey, data management and data analysis, and to Strategic Health Outcomes, Inc., for writing and editorial assistance. Hideyuki Imagawa and Taro Goto are employed by Eli Lilly Japan K.K. and William Montgomery by Eli Lilly Australia Pty Ltd. All are minor stockholders of Eli Lilly and Company. The specific roles of these authors are articulated in the author contributions section. Eli Lilly is the patent holder and marketing sponsor of Strattera (atomoxetine hydrochloride, patent number 5.658.590). There are no other patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2015","07","Eiji Kirino","EK",4,TRUE,4,NA,4,4,TRUE,TRUE,FALSE,0,NA,FALSE
